系统免疫炎症指数与泌尿系恶性肿瘤预后关系的研究进展
Research Progress on the Relationship between Systemic Immune Inflammation Index and Prognosis of Malignant Tumors in the Urinary System
DOI: 10.12677/ACM.2023.1381904, PDF,   
作者: 崔刘龙：青海大学研究生院，青海 西宁；陈国俊：青海大学附属医院泌尿外科，青海 西宁
关键词: 系统免疫炎症指数；泌尿系统肿瘤；病理特征；预后；Systemic Immune Inflammation Index； Urinary System Tumor； Pathological Characteristics； Prognosis
摘要: 全身炎症反应在促进肿瘤进展中起重要作用。系统免疫炎症指数(systemic immune inflammation index, SII)作为一种全身炎症反应的评价指标，被认为是结直肠癌、胃癌、乳腺癌等多种癌症预后的独立危险因素，可以预测多种恶性肿瘤患者的生存情况。近年来其与泌尿系恶性肿瘤预后间相关性的研究也得到广泛开展。本文对近年来SII与泌尿系恶性肿瘤预后之间关系的临床研究进行综述，旨在为临床判断泌尿系统恶性肿瘤患者的预后转归提供帮助。
Abstract: Systemic inflammatory response plays an important role in promoting tumor progression. The sys-temic immune inflammation index (SII), as an evaluation index of systemic inflammatory reaction, is considered as an independent risk factor for the prognosis of colorectal cancer, gastric cancer, breast cancer and other cancers, and can predict the survival of patients with various malignant tumors. In recent years, research on the correlation between it and the prognosis of malignant tu-mors in the urinary system has also been widely carried out. This article reviews the clinical studies on the relationship between SII and the prognosis of urinary system malignancies in recent years, in order to provide help for clinical judgment of the prognosis of patients with urinary system ma-lignancies.
文章引用：崔刘龙, 陈国俊. 系统免疫炎症指数与泌尿系恶性肿瘤预后关系的研究进展[J]. 临床医学进展, 2023, 13(8): 13622-13629. https://doi.org/10.12677/ACM.2023.1381904

参考文献

[1] Wiseman, M.J. (2019) Nutrition and Cancer: Prevention and Survival. British Journal of Nutrition, 122, 481-487. [Google Scholar] [CrossRef] 
[2] Cao, M.M., et al. (2022) Current Cancer Burden in China: Epi-demiology, Etiology, and Prevention. Cancer Biology & Medicine, 19, 1121-1138. [Google Scholar] [CrossRef] [PubMed]
[3] Kitamura, T., Qian, B.Z. and Pollard, J.W. (2015) Im-mune Cell Promotion of Metastasis. Nature Reviews Immunology, 15, 73-86. [Google Scholar] [CrossRef] [PubMed]
[4] Wculek, S.K. and Malanchi, I. (2015) Neutrophils Support Lung Colonization of Metastasis-Initiating Breast Cancer Cells. Nature, 528, 413-417. [Google Scholar] [CrossRef] [PubMed]
[5] Hu, B., Yang, X.R., Xu, Y., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222. [Google Scholar] [CrossRef] 
[6] Chen, J.H., Zhai, E.T., Yuan, Y.J., et al. (2017) Systemic Immune-Inflammation Index for Predicting Prognosis of Colorectal Cancer. World Journal of Gastroenterology, 23, 6261-6272. [Google Scholar] [CrossRef] [PubMed]
[7] Qiu, Y., Zhang, Z. and Chen, Y. (2021) Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Gastric Cancer: A Meta-Analysis. Frontiers in Oncology, 11, Article ID: 537140. [Google Scholar] [CrossRef] [PubMed]
[8] Zhang, Y., Sun, Y. and Zhang, Q. (2020) Prognostic Value of the Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Meta-Analysis. Cancer Cell International, 20, Article No. 224. [Google Scholar] [CrossRef] [PubMed]
[9] Li, J., Cao, D., Huang, Y., et al. (2022) The Prognostic and Clinicopathologf:ical Significance of Systemic Immune-Inflammation Index in Bladder Cancer. Frontiers in Immunology, 13, Article ID: 865643. [Google Scholar] [CrossRef] [PubMed]
[10] Qi, W., Zhou, Y., Liu, Z., et al. (2022) Revealing the Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Patients with Different Stage Prostate Cancer: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 9, Article ID: 1052943. [Google Scholar] [CrossRef] [PubMed]
[11] Ohno, Y. (2019) Role of Systemic Inflammatory Response Markers in Urological Malignancy. International Journal of Urology, 26, 31-47. [Google Scholar] [CrossRef] [PubMed]
[12] Güngör, N., Knaapen, A.M., Munnia, A., et al. (2010) Genotoxic Effects of Neutrophils and Hypochlorous Acid. Mutagenesis, 25, 149-154. [Google Scholar] [CrossRef] [PubMed]
[13] Sandhu, J.K., Privora, H.F., Wenckebach, G., et al. (2000) Neutrophils, Nitric Oxide Synthase, and Mutations in the Mutatect Murine Tumor Model. The American Journal of Pathology, 156, 509-518. [Google Scholar] [CrossRef] 
[14] Butin-Israeli, V., Bui, T.M., Wiesolek, H.L., et al. (2019) Neutrophil-Induced Genomic Instability Impedes Resolution of Inflammation and Wound Healing. Journal of Clinical Investigation, 129, 712-726. [Google Scholar] [CrossRef] 
[15] Rodríguez-Berriguete, G., Sánchez-Espiridión, B., Cansino, J.R., et al. (2013) Clinical Significance of both Tumor and Stromal Expression of Components of the IL-1 and TNF-α Signaling Pathways in Prostate Cancer. Cytokine, 64, 555-563. [Google Scholar] [CrossRef] [PubMed]
[16] Deryugina, E.I., Zajac, E., Juncker-Jensen, A., et al. (2014) Tissue-Infiltrating Neutrophils Constitute the Major in Vivo Source of Angiogenesis-Inducing MMP-9 in the Tumor Microenvironment. Neoplasia, 16, 771-788. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, Z., Yang, C., Li, L., et al. (2020) Tumor-Derived HMGB1 Induces CD62L(dim) Neutrophil Polarization and Promotes Lung Metastasis in Triple-Negative Breast Cancer. Onco-genesis, 9, Article No. 82. [Google Scholar] [CrossRef] [PubMed]
[18] Morimoto-Kamata, R. and Yui, S. (2017) Insulin-Like Growth Factor-1 Signaling Is Responsible for Cathepsin G-Induced Aggregation of Breast Cancer MCF-7 Cells. Cancer Science, 108, 1574-1583. [Google Scholar] [CrossRef] [PubMed]
[19] Olsson, A.K. and Cedervall, J. (2018) The Pro-Inflammatory Role of Plate-lets in Cancer. Platelets, 29, 569-573. [Google Scholar] [CrossRef] [PubMed]
[20] Liu, Y., Zhang, Y., Ding, Y., et al. (2021) Platelet-Mediated Tumor Metastasis Mechanism and the Role of Cell Adhesion Molecules. Critical Reviews in Oncology/Hematology, 167, Article ID: 103502. [Google Scholar] [CrossRef] [PubMed]
[21] Yan, M. and Jurasz, P. (2016) The Role of Platelets in the Tumor Microenvironment: From Solid Tumors to Leukemia. Biochimica et Biophysica Acta, 1863, 392-400. [Google Scholar] [CrossRef] [PubMed]
[22] Marra, P., Mathew, S., Grigoriadis, A., et al. (2014) IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers. Cancer Research, 74, 4908-4921. [Google Scholar] [CrossRef] 
[23] Mantovani, A., Allavena, P., Sica, A., et al. (2008) Can-cer-Related Inflammation. Nature, 454, 436-444. [Google Scholar] [CrossRef] [PubMed]
[24] Gooden, M.J., de Bock G.H., Leffers, N., et al. (2011) The Prognostic Influence of Tumour-Infiltrating Lymphocytes in Cancer: A Systematic Review with Meta-Analysis. British Journal of Cancer, 105, 93-103. [Google Scholar] [CrossRef] [PubMed]
[25] Ray-Coquard, I., Cropet, C., Van Glabbeke, M., et al. (2009) Lympho-penia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. Cancer Re-search, 69, 5383-5391. [Google Scholar] [CrossRef] 
[26] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Can-cer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[27] Peng, D., Gong, Y.Q., Hao, H., et al. (2017) Preoperative Prognostic Nu-tritional Index Is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: A Retrospective Study. BMC Cancer, 17, Article No. 391. [Google Scholar] [CrossRef] [PubMed]
[28] Kang, M., Jeong, C.W., Kwak, C., et al. (2017) Preoperative Neutrophil-Lymphocyte Ratio Can Significantly Predict Mortality Outcomes in Patients with Non-Muscle Invasive Bladder Cancer Undergoing Transurethral Resection of Bladder Tumor. Oncotarget, 8, 12891-12901. [Google Scholar] [CrossRef] [PubMed]
[29] Kamoun, A., de Reyniès, A., Allory, Y., et al. (2020) A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. European Urology, 77, 420-433. [Google Scholar] [CrossRef] [PubMed]
[30] 李攀, 王博文一, 洪星磊, 等. 术前系统免疫炎症指数对非肌层浸润性膀胱癌预后的评估价值[J]. 肿瘤基础与临床, 2022, 35(1): 23-27.
[31] Gorgel, S.N., Akin, Y., Koc, E.M., et al. (2020) Retrospective Study of Systemic Immune-Inflammation Index in Muscle Invasive Bladder Cancer: In-itial Results of Single Centre. International Urology and Nephrology, 52, 469-473. [Google Scholar] [CrossRef] [PubMed]
[32] Liu, P., Chen, S., Gao, X., et al. (2022) Preoperative Sarcopenia and Systemic Immune-Inflammation Index Can Predict Response to Intravesical Bacillus Calmette-Guerin Instillation in Patients with Non-Muscle Invasive Bladder Cancer. Frontiers in Immunology, 13, Article ID: 1032907. [Google Scholar] [CrossRef] [PubMed]
[33] Zhou, Y., Zhang, Y., Li, W., et al. (2020) TCEAL2 as a Tumor Suppressor in Renal Cell Carcinoma Is Associated with the Good Prognosis of Patients. Cancer Management and Re-search, 12, 9589-9597. [Google Scholar] [CrossRef] 
[34] Hammers, H.J., Plimack, E.R., Infante, J.R., et al. (2017) Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology, 35, 3851-3858. [Google Scholar] [CrossRef] 
[35] Ljungberg, B., Al-biges, L., Abu-Ghanem, Y., et al. (2019) European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology, 75, 799-810. [Google Scholar] [CrossRef] [PubMed]
[36] Unverzagt, S., Moldenhauer, I., Nothacker, M., et al. (2017) Immunotherapy for Metastatic Renal Cell Carcinoma. Cochrane Database of Systematic Reviews, 5, D11673. [Google Scholar] [CrossRef] 
[37] Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. [Google Scholar] [CrossRef] [PubMed]
[38] Jin, M., Yuan, S., Yuan, Y., et al. (2021) Prognostic and Clinicopatholog-ical Significance of the Systemic Immune-Inflammation Index in Patients with Renal Cell Carcinoma: A Meta-Analysis. Frontiers in Oncology, 11, Article ID: 735803. [Google Scholar] [CrossRef] [PubMed]
[39] Ozbek, E., Be-siroglu, H., Ozer, K., et al. (2020) Systemic Immune Inflammation Index Is a Promising Non-Invasive Marker for the Prognosis of the Patients with Localized Renal Cell Carcinoma. International Urology and Nephrology, 52, 1455-1463. [Google Scholar] [CrossRef] [PubMed]
[40] Teishima, J., Inoue, S., Hayashi, T., et al. (2020) Impact of the Systemic Immune-Inflammation Index for the Prediction of Prognosis and Modification of the Risk Model in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors. Canadian Urological Associa-tion Journal, 14, E582-E587. [Google Scholar] [CrossRef] [PubMed]
[41] Bedke, J., Albiges, L., Capitanio, U., et al. (2021) The 2021 Updated Euro-pean Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-Based Combination Therapies for Treatment-Naive Metastatic Clear-Cell Renal Cell Carcinoma Are Standard of Care. European Urology, 80, 393-397. [Google Scholar] [CrossRef] [PubMed]
[42] Massari, F., Rizzo, A., Mollica, V., et al. (2021) Immune-Based Combinations for the Treatment of Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomised Clinical Trials. European Journal of Cancer, 154, 120-127. [Google Scholar] [CrossRef] [PubMed]
[43] Stühler, V., Herrmann, L., Rausch, S., et al. (2022) Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipili-mumab plus Nivolumab. Cancers (Basel), 14, Article No. 2972. [Google Scholar] [CrossRef] [PubMed]
[44] 蔡会龙, 原伟光, 刘思奇, 等. 1990年和2019年中国前列腺癌疾病负担及危险因素研究[J]. 临床泌尿外科杂志, 2022, 37(10): 749-752.
[45] Dong, L., Su, Y., Zhu, Y., et al. (2022) The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy. Journal of Nuclear Medicine, 63, 248-252. [Google Scholar] [CrossRef] [PubMed]
[46] Schwarzenboeck, S.M., Rauscher, I., Bluemel, C., et al. (2017) PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 58, 1545-1552. [Google Scholar] [CrossRef] [PubMed]
[47] Rajwa, P., Schuettfort, V.M., D’Andrea, D., et al. (2021) Impact of Systemic Immune-Inflammation Index on Oncologic Outcomes in Patients Treated with Radical Prostatectomy for Clinically Nonmetastatic Prostate Cancer. Urologic Oncology, 39, 719-785. [Google Scholar] [CrossRef] [PubMed]
[48] Wang, S., Yang, X., Yu, Z., et al. (2022) The Values of Sys-temic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in Predicting Biochemical Recurrence in Patients with Localized Prostate Cancer after Radical Prostatectomy. Frontiers in Oncology, 12, Article ID: 907625. [Google Scholar] [CrossRef] [PubMed]
[49] Zhang, B. and Xu, T. (2023) Prognostic Significance of Pretreat-ment Systemic Immune-Inflammation Index in Patients with Prostate Cancer: A Meta-Analysis. World Journal of Surgi-cal Oncology, 21, Article No. 2. [Google Scholar] [CrossRef] [PubMed]
[50] Man, Y.N. and Chen, Y.F. (2019) Systemic Im-mune-Inflammation Index, Serum Albumin, and Fibrinogen Impact Prognosis in Castration-Resistant Prostate Cancer Patients Treated with First-Line Docetaxel. International Urology and Nephrology, 51, 2189-2199. [Google Scholar] [CrossRef] [PubMed]
[51] Neuberger, M., Skladny, J., Goly, N., et al. (2022) Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hor-mone-Sensitive Prostate Cancer Treated with Docetaxel Chemotherapy. AntiCancer Research, 42, 1911-1918. [Google Scholar] [CrossRef] [PubMed]

为你推荐